Centene Crecimiento futuro
Future controles de criterios 1/6
Centene se prevé un crecimiento anual de los beneficios y los ingresos de 9.4% y 3% respectivamente. Se prevé que el BPA sea de grow en 14.4% al año. Se prevé que la rentabilidad de los fondos propios sea de 14% en 3 años.
Información clave
9.0%
Tasa de crecimiento de los beneficios
13.1%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Healthcare | 12.1% |
Tasa de crecimiento de los ingresos | 4.9% |
Rentabilidad financiera futura | 14.3% |
Cobertura de analistas | Good |
Última actualización | 11 Apr 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Centene Corporation Still An Opportunity With An A-Grade Valuation
Mar 31If EPS Growth Is Important To You, Centene (NYSE:CNC) Presents An Opportunity
Mar 15Market Still Lacking Some Conviction On Centene Corporation (NYSE:CNC)
Feb 08Centene: Stay Defensive Amid Economic Uncertainty With This Low-Beta Bargain
Jan 22Is Centene (NYSE:CNC) Using Too Much Debt?
Jan 21Centene: Overlooked Healthcare Giant
Nov 21Does Centene (NYSE:CNC) Deserve A Spot On Your Watchlist?
Nov 10Centene: Solid Performance With Positive Outlook, But Limited Upside Potential
Oct 26These 4 Measures Indicate That Centene (NYSE:CNC) Is Using Debt Reasonably Well
Oct 22Decoding Centene: Why I Think It's Undervalued
Oct 10If EPS Growth Is Important To You, Centene (NYSE:CNC) Presents An Opportunity
Jul 31Centene: Results Impress But Buyers Aren't Swarming Yet
Jul 27Centene (NYSE:CNC) Has A Pretty Healthy Balance Sheet
Jul 12Centene (NYSE:CNC) Seems To Use Debt Quite Sensibly
Apr 10Centene Non-GAAP EPS of $0.86 beats by $0.02, revenue of $35.56B beats by $190M
Feb 07With EPS Growth And More, Centene (NYSE:CNC) Makes An Interesting Case
Jan 27Centene (NYSE:CNC) Seems To Use Debt Rather Sparingly
Dec 27Centene: Once Again, With Quality, Now A 'Buy'
Dec 23Centene appoints new leadership; Ken Fasola President of Centene, Dave Thomas CEO of Medicaid
Dec 14An Intrinsic Calculation For Centene Corporation (NYSE:CNC) Suggests It's 50% Undervalued
Nov 11Is Now The Time To Put Centene (NYSE:CNC) On Your Watchlist?
Oct 26Centene Q3 2022 Earnings Preview
Oct 24Centene: Future Growth Will Exceed Market Expectations
Oct 14Centene: A Chaos Stock
Sep 28Does Centene (NYSE:CNC) Have A Healthy Balance Sheet?
Sep 20Centene falls 7%, most since April 2021, on surging volume
Sep 14If EPS Growth Is Important To You, Centene (NYSE:CNC) Presents An Opportunity
Jul 28Centene Q2 2022 Earnings Preview
Jul 25Centene Keeps Overdelivering - But Is Expensive
Jul 11Is Centene (NYSE:CNC) Using Too Much Debt?
Jun 16Centene: Solid Q122 Earnings For Health Insurer Helps Make Buy/Hold Case
Apr 28Centene Has Overdelivered - It Is Time For A 'Hold'
Mar 24We Think Centene (NYSE:CNC) Can Stay On Top Of Its Debt
Mar 14Centene: Finally Gets Respect And Is Poised To Profit
Dec 31Is Centene (NYSE:CNC) A Risky Investment?
Dec 13Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | 162,536 | 3,635 | 4,348 | 5,549 | 8 |
12/31/2025 | 152,793 | 3,232 | 4,344 | 5,142 | 13 |
12/31/2024 | 146,138 | 2,984 | 4,271 | 5,828 | 12 |
12/31/2023 | 141,266 | 2,702 | 7,254 | 8,053 | N/A |
9/30/2023 | 139,364 | 2,444 | 5,451 | 6,260 | N/A |
6/30/2023 | 138,111 | 2,713 | 7,651 | 8,571 | N/A |
3/31/2023 | 137,020 | 1,483 | 8,392 | 9,379 | N/A |
12/31/2022 | 135,999 | 1,202 | 5,257 | 6,261 | N/A |
9/30/2022 | 132,756 | 2,014 | 7,493 | 8,512 | N/A |
6/30/2022 | 129,228 | 1,860 | 5,985 | 6,982 | N/A |
3/31/2022 | 124,181 | 1,497 | 4,348 | 5,313 | N/A |
12/31/2021 | 118,573 | 1,347 | 3,295 | 4,205 | N/A |
9/30/2021 | 114,130 | 736 | 5,643 | 6,511 | N/A |
6/30/2021 | 111,284 | 720 | 2,863 | 3,757 | N/A |
3/31/2021 | 108,158 | 2,461 | 4,907 | 5,786 | N/A |
12/31/2020 | 104,280 | 1,808 | 4,634 | 5,503 | N/A |
9/30/2020 | 95,764 | 2,029 | 1,008 | 1,871 | N/A |
6/30/2020 | 86,523 | 1,556 | 1,918 | 2,724 | N/A |
3/31/2020 | 78,105 | 845 | -804 | -73 | N/A |
12/31/2019 | 70,807 | 1,321 | 753 | 1,483 | N/A |
9/30/2019 | 68,385 | 1,353 | 784 | 1,500 | N/A |
6/30/2019 | 65,507 | 1,277 | 1,498 | 2,147 | N/A |
3/31/2019 | 61,028 | 1,082 | 71 | 704 | N/A |
12/31/2018 | 56,688 | 900 | 559 | 1,234 | N/A |
9/30/2018 | 52,618 | 889 | 1,708 | 2,318 | N/A |
6/30/2018 | 48,655 | 1,075 | 1,264 | 1,867 | N/A |
3/31/2018 | 47,201 | 1,029 | 1,530 | 2,087 | N/A |
12/31/2017 | 45,810 | 828 | 1,067 | 1,489 | N/A |
9/30/2017 | 44,870 | 853 | N/A | 2,631 | N/A |
6/30/2017 | 43,646 | 796 | N/A | 3,016 | N/A |
3/31/2017 | 42,468 | 713 | N/A | 2,903 | N/A |
12/31/2016 | 37,693 | 562 | N/A | 1,851 | N/A |
9/30/2016 | 32,839 | 416 | N/A | 460 | N/A |
6/30/2016 | 28,062 | 360 | N/A | 40 | N/A |
3/31/2016 | 22,948 | 277 | N/A | 809 | N/A |
12/31/2015 | 21,292 | 356 | N/A | 658 | N/A |
9/30/2015 | 19,854 | 350 | N/A | 827 | N/A |
6/30/2015 | 18,548 | 339 | N/A | 1,206 | N/A |
3/31/2015 | 17,102 | 298 | N/A | 1,016 | N/A |
12/31/2014 | 15,689 | 268 | N/A | 1,223 | N/A |
9/30/2014 | 14,134 | 210 | N/A | 1,023 | N/A |
6/30/2014 | 12,700 | 179 | N/A | 713 | N/A |
3/31/2014 | 11,475 | 172 | N/A | 591 | N/A |
12/31/2013 | 10,544 | 161 | N/A | 382 | N/A |
9/30/2013 | 9,427 | 209 | N/A | 183 | N/A |
6/30/2013 | 8,932 | 162 | N/A | 370 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. tasa de ahorro: CNC(9.2% al año) es superior a la tasa de ahorro (2.2%).
Beneficios frente mercado: CNCSe prevé que los beneficios de la empresa (9.4% al año) crezcan menos que el mercado US (14.9% al año).
Beneficios de alto crecimiento: CNCSe prevé que los beneficios de la empresa crezcan, pero no significativamente.
Ingresos vs. Mercado: CNC(3% al año) se prevé que crezca más despacio que el mercado de US (8.1% al año).
Ingresos de alto crecimiento: CNCSe prevé que los ingresos de la empresa (3% al año) crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
Futura rentabilidad financiera (ROE): CNCSe prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (14%).